KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed EBITDA Margin for 17 consecutive years, with 17.24% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 8807.0% year-over-year to 17.24%; the TTM value through Mar 2026 reached 12.01%, up 2552.0%, while the annual FY2025 figure was 8.84%, 2170.0% up from the prior year.
  • EBITDA Margin hit 17.24% in Q1 2026 for Alnylam Pharmaceuticals, up from 10.32% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 20.76% in Q3 2025 and bottomed at 154.17% in Q3 2022.
  • Average EBITDA Margin over 5 years is 40.49%, with a median of 20.31% recorded in 2024.
  • Year-over-year, EBITDA Margin surged 17449bps in 2023 and then tumbled -5676bps in 2025.
  • Alnylam Pharmaceuticals' EBITDA Margin stood at 62.19% in 2022, then surged by 53bps to 29.32% in 2023, then soared by 46bps to 15.76% in 2024, then skyrocketed by 166bps to 10.32% in 2025, then surged by 67bps to 17.24% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 17.24%, 10.32%, and 20.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.